The Parkinson Progression Marker Initiative (PPMI).
The Parkinson Progression Marker Initiative (PPMI).
复制标题
DOI：
10.1016/j.pneurobio.2011.09.005
复制
发表时间：
2011-12
影响因子：
6.7
通讯作者：
Taylor, Peggy
中科院分区：
文献类型：
--
作者：
Marek, Kenneth;Jennings, Danna;Lasch, Shirley;Siderowf, Andrew;Tanner, Caroline;Simuni, Tanya;Coffey, Chris;Kieburtz, Karl;Flagg, Emily;Chowdhuty, Sohini;Poewe, Werner;Mollenhauer, Brit;Sherer, Todd;Frasier, Mark;Meunier, Claire;Rudolph, Alice;Casaceli, Cindy;Seibyl, John;Mendick, Susan;Schuff, Norbert;Zhang, Ying;Toga, Arthur;Crawford, Karen;Ansbach, Alison;Piovella, Michele;Trojanowski, John;Shaw, Les;Singleton, Andrew;Hawkins, Keith;Eberling, Jamie;Brooks, Deborah;Russell, David;Leary, Laura;Factor, Stewart;Sommerfeld, Barbara;Hogarth, Penelope;Pighetti, Emily;Williams, Karen;Standaert, David;Guthrie, Stephanie;Hauser, Robert;Delgado, Holly;Jankovic, Joseph;Hunter, Christine;Stern, Matthew;Baochan Tran;Leverenz, Jim;Baca, Marne;Frank, Sam;Thomas, Cathi-Ann;Richard, Irene;Deeley, Cheryl;Rees, Linda;Sprenger, Fabienne;Lang, Elisabeth;Shill, Holly;Obradov, Sanja;Fernandez, Hubert;Winters, Adrienna;Berg, Daniela;Gauss, Katharina;Galasko, Douglas;Fontaine, Deborah;Mari, Zoltan;Gerstenhaber, Melissa;Brooks, David;Malloy, Sophie;Barone, Paolo;Longo, Katia;Comery, Tom;Ravina, Bernard;Grachev, Igor;Gallagher, Kim;Collins, Michelle;Widnell, Katherine L.;Ostrowizki, Suzanne;Fontoura, Paulo;La-Roche, Hoffmann;Ho, Tony;Luthman, Johan;van der Brug, Marcel;Reith, Alastair D.;Taylor, Peggy
关键词：
帕金森进展标志物计划（PPMI）是一项综合性观察性、国际性、多中心研究，旨在确定PD进展生物标志物，以提高对疾病病因和病程的理解，并提供关键工具，提高PD改良治疗试验成功的可能性。PPMI队列将包括400名最近诊断的PD和200名健康受试者，这些受试者在21个临床研究中心使用标准化数据采集方案进行临床、成像和生物标本生物标志物评估。所有研究数据将被整合到PPMI研究数据库中，并将通过PPMI网站（www.ppmi-info.org）快速、准确地获得。科学家可通过向独立的PPMI生物样本审查委员会申请，也可通过PPMI网站获得生物样本，包括血液、脑脊液（CSF）和尿液的纵向采集。PPMI将依靠政府、PD基金会、工业和学术界的合作伙伴关系。这种方法对于提高这一雄心勃勃的战略的成功潜力至关重要，该战略旨在开发PD进展生物标志物，从而加速疾病修饰疗法的研究。
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multicenter study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.
登录
查看更多内容
DOI：
10.1073/pnas.0610204104
发表时间：
2007-01-16
影响因子：
11.1
作者：
Scherzer, Clemens R.;Eklund, Aron C.;Gullans, Steven R.
通讯作者：
Gullans, Steven R.
影响因子：
11.2
作者：
Olanow, C. Warren;Kleburtz, Karl;Schapira, Anthony H. V.
通讯作者：
Schapira, Anthony H. V.
影响因子：
2.1
作者：
Peskind E;Nordberg A;Darreh-Shori T;Soininen H
通讯作者：
Soininen H
影响因子：
11.2
作者：
Langston, JW
通讯作者：
Langston, JW
影响因子：
158.5
作者：
Olanow, C. Warren;Rascol, Olivier;Tolosa, Eduardo
通讯作者：
Tolosa, Eduardo